Tag: MCL

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Onclive28

Brexucabtagene Autoleucel Displays Continued Durability, Safety in Relapsed/Refr...

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

Visit website
onclive6

Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL

  Mar 03 2021 Tagged mAbs, MCL, CLL

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
Immunotherapy Web Featured Images 85

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Visit website
Immunotherapy Web Featured Images 66

Interim data from phase II Zuma-5 study (axicabtagene ciloleucel in FL and MZL) ...

Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone lymphoma, called MZL, who received at least two prior therapy lines, according to interim data from a Phase 2 trial.

Visit website
Onclive3

CAR T-Cell Combinations May Offer a Way to Overcome Antigen Escape in MCL

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

Visit website
Immunotherapy Web Featured Images 10

Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymph...

A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).

Visit website
ImmunotherapyWebsite Images Featured 35

Exploring Targeted and CAR T-Cell Therapies on the Horizon for MCL

  Sep 25 2020 Tagged CAR-T, MCL, NHL

Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.

Visit website